Name: Q&A with Oncimmune CEO, Dr Adam M Hill and Chairman Alistair Macdonald
Uploaded: 2022-10-05T06:52:16.091425+00:00
Duration: 1768 s
Channel: Vox Markets

Vox Markets

In this interview CEO Adam Hill & non-exec Chair Alistair Macdonald of Oncimmune take Vox Markets through:

Chairman's 1st impressions since joining, & where he's like to take the group. Start
Order progression & pipeline. 02:10
Typical contract sizes & work completed. 05:05
Strategic importance of obtaining preferred supplier status with Biopharmas. 08:55
Where new business is being won. 11:35
How to scale the group. 14:05
Underlying profitability of ImmunoINSIGHTS. 17:30
Progress on earlyCDT test. 18:45
M&A. 21:20
Funding position. 23:30
Ultimate goals over next 2-4 years. 24:45
Future newsflow. 27:25

In this interview CEO Adam Hill &amp; non-exec Chair Alistair Macdonald of Oncimmune take Vox Markets through:Chairman's 1st impressions since joining, &amp; where he's like to take the group. Start Order progression &amp; pipeline. 02:10 Typical contract sizes &amp; work completed. 05:05 Strategic importance of obtaining preferred supplier status with Biopharmas. 08:55 Where new business is being won. 11:35 How to scale the group. 14:05 Underlying profitability of ImmunoINSIGHTS. 17:30 Progress on earlyCDT test. 18:45 M&amp;A. 21:20 Funding position. 23:30 Ultimate goals over next 2-4 years. 24:45 Future newsflow. 27:25

Chairman's 1st impressions since joining, & where he's like to take the group

Order progression & pipeline.

Typical contract sizes & work completed

Strategic importance of obtaining preferred supplier status with Biopharmas

Where new business is being won

How to scale the group

Underlying profitability of ImmunoINSIGHTS

Progress on earlyCDT test

Funding position

Ultimate goals over next 2-4 years

Future newsflow

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/186/005186/video_9t091fK.mp4